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Abstract
Background: Despite latest advances in prostate cancer (PCa) therapy, PCa remains the third-leading cause of
cancer-related death in European men. Dysregulation of microRNAs (miRNAs), small non-coding RNA molecules
with gene expression regulatory function, has been reported in all types of epithelial and haematological cancers.
In particular, miR-221-5p alterations have been reported in PCa.
Methods: miRNA expression data was retrieved from a comprehensive publicly available dataset of 218 PCa
patients (GSE21036) and miR-221-5p expression levels were analysed. The functional role of miR-221-5p was
characterised in androgen- dependent and androgen- independent PCa cell line models (C4–2 and PC-3M-
Pro4 cells) by miR-221-5p overexpression and knock-down experiments. The metastatic potential of highly
aggressive PC-3M-Pro4 cells overexpressing miR-221-5p was determined by studying extravasation in a zebrafish
model. Finally, the effect of miR-221-5p overexpression on the growth of PC-3M-Pro4luc2 cells in vivo was studied
by orthotopic implantation in male Balb/cByJ nude mice and assessment of tumor growth.
Results: Analysis of microRNA expression dataset for human primary and metastatic PCa samples and control
normal adjacent benign prostate revealed miR-221-5p to be significantly downregulated in PCa compared to
normal prostate tissue and in metastasis compared to primary PCa. Our in vitro data suggest that miR-221-5p
overexpression reduced PCa cell proliferation and colony formation. Furthermore, miR-221-5p overexpression
dramatically reduced migration of PCa cells, which was associated with differential expression of selected EMT
markers. The functional changes of miR-221-5p overexpression were reversible by the loss of miR-221-5p levels,
indicating that the tumor suppressive effects were specific to miR-221-5p. Additionally, miR-221-5p overexpression
significantly reduced PC-3M-Pro4 cell extravasation and metastasis formation in a zebrafish model and decreased
tumor burden in an orthotopic mouse model of PCa.
Conclusions: Together these data strongly support a tumor suppressive role of miR-221-5p in the context of PCa and
its potential as therapeutic target.
Keywords: Prostate cancer, miR-221-5p, Proliferation, Migration, Tumor suppressor miRNA
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: marianna.kruithofdejulio@dbmr.unibe.ch;
eugenio.zoni@dbmr.unibe.ch
†Martin Spahn, Marianna Kruithof-de Julio and Eugenio Zoni contributed
equally to this work.
1Urology Research Laboratory, Department for BioMedical Research,
University of Bern, Bern, Switzerland
Full list of author information is available at the end of the article
Kiener et al. BMC Cancer          (2019) 19:627 
https://doi.org/10.1186/s12885-019-5819-6
Background
Prostate cancer (PCa) is the most commonly diagnosed
cancer and the third leading cause of cancer-related
death in European men [1]. Radical prostatectomy (RP)
and radiotherapy are the standard of care to treat pri-
mary prostate adenocarcinoma and 70% of patients will
be cured [2, 3]. Androgen deprivation therapy (ADT) is
often applied as adjuvant treatment for radiotherapy or
to treat advanced, hormone sensitive tumors [4] but
most patients will develop castration-resistant PCa
(CRPC) and progress to metastatic disease, which com-
prises the most lethal phase of PCa [2]. To date, treatment
options for this stage of the disease are limited [5, 6]. New
therapeutic strategies are therefore urgently required.
miRNAs have been suggested as diagnostic and prognostic
biomarkers and their application as new molecular thera-
peutic strategies in cancer and other diseases is currently
under investigation [7–10].
MicroRNAs (miRNAs) are 19-25 nt long small non-
coding RNAs that modulate a multitude of biological
processes by negative regulation of their target mRNAs
[11, 12]. miRNAs are encoded in introns or separate
genes [13–15] and transcribed into a long primary tran-
script (pri-miR), which is cut by Drosha/DGCR8 com-
plex into the ~ 70 nucleotide long precursor miRNA
(pre-miRNA). In the cytoplasm, the pre-miRNA is proc-
essed by Dicer into the mature miRNA and incorporated
into the Argonaut complex to regulate mRNA stability
and translation via binding in the 3’UTR of its target
mRNA [16, 17]. miRNAs have been found to be dysreg-
ulated in all types of cancer [18, 19] and some exert
oncogenic or tumor suppressive function (oncomiRs)
[20]. miR-221 is a cancer-associated miRNA [21]. It is
encoded in a gene cluster together with miR-222 on the
short arm of the X chromosome. miR-221/− 222 are
transcribed together into the pri-miRNA, which is fur-
ther processed to mature miR-221-3p and the passenger
miR-221-5p to regulate gene expression [22].
miR-221 is overexpressed in a variety of epithelial can-
cers including breast, liver, bladder, pancreas, gastric,
colorectal cancer, melanoma, papillary thyroid carcin-
oma and glioblastoma [21, 23]. In PCa miR-221 upregu-
lation [24, 25] as well as miR-221 downregulation has
been reported [26–30]. Due to the strong downregula-
tion of miR-221 in PCa tissue and in the blood of PCa
patients, miR-221 has been suggested as prognostic and
predictive biomarker in PCa [31–33]. However, the role
of miR-221 in tumorigenesis and cancer progression is
controversial. miR-221-3p has been investigated exten-
sively compared to miR-221-5p. In vivo studies demon-
strated that miR-221/222 downregulation impairs the
growth of PCa xenografts implying that miR-221-3p acts
as oncogenic miRNA in PCa [34]. Moreover, miR-221-3p
promotes proliferation of PCa cells by direct interaction
and downregulation of p27/Kip1 [35]. Other tumor sup-
pressors targeted by miR-221-3p include p57/Kip2, PTEN,
TIMP3 and PUMA [36–38] . In contrast, miR-221-3p can
act as tumor suppressor via downregulation of oncogenic
c-kit, thereby regulating angiogenesis [39] and inhibiting
the growth of erythroleukemic cells [40]. Moreover, it has
been shown to reduce proliferation of PCa cells via down-
regulation of Bmi-1 [41], SOCS3 and IRF2 [42] and inhibit
migration and invasion by targeting Ecm29 [28].
miR-221-5p exerts tumor suppressive function in colo-
rectal cancer, reducing metastatic burden in vivo [43].
However, miR-221-5p shows oncogenic function by tar-
geting SOCS1 in PCa cells. Consequently, silencing of
miR-221-5p reduced tumor growth in vivo in a xenograft
mouse model [44]. These studies indicate that despite
relatively consistent reports of miR-221 downregulation in
PCa its role in tumorigenesis is still unclear.
In this study we characterized the effects of miR-221-
5p overexpression and downregulation in vitro in two
human PCa cell lines (PC-3M-Pro4luc2 cells and C4–2
cells) and investigated the function of miR-221-5p in
two in vivo models. Our results demonstrate tumor sup-
pressive function of miR-221-5p in the context of PCa
and support the inverse correlation between miR-221-5p
expression and disease progression in microRNA expres-
sion dataset [45]. We show that miR-221-5p overexpres-
sion decreased proliferation and migration of PCa cell
lines. Consistently with our in vitro data, miR-221-5p
overexpression reduced tumor burden in vivo in a zebra-
fish model of cancer cell extravasation and in a xeno-
graft mouse model of tumor growth.
Methods
Analysis of microRNA dataset
miR-221 (3p and 5p) expression in PCa patients was
analysed in a publicly available dataset of 28 normal
prostate samples and 113 tumor samples (99 primary
and 14 metastatic samples; GSE21036) [45]. miR-221-5p
and -3p expression data from GSE21036 dataset was ex-
tracted with R using shinyGEO [46].
Cell culture
Normal prostatic epithelial cell line, Ep156T, was derived
from normal tissue of a PCa patient undergoing radical
prostatectomy [47] and cultured in MCDB-153 medium
(Sigma Aldrich) containing 1.2 g/L NaHCO3 (Sigma
Aldrich) and supplemented with 1% FBS (Seraglob,
Bioswisstec Ltd), 1% Penicillin/Streptomycin (100 U/L/
100 μg/ml; Sigma Aldrich), 1% non-essential amino acids
(without L-Glutamine; Gibco®, ThermoFisher Scientific),
200 nM Hydrocortisone (Sigma Aldrich), 10 nM Dihydro-
testosterone (DHT; Fluka Chemica), 10 nM Triiodothyr-
onine (T3; Sigma Aldrich), 1% Insulin-transferrin-selenium
(Gibco®, ThermoFisher Scientific), 5 ng/ml EGF (Peprotech),
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50 μg/ml bovine pituitary extract (Gibco®, ThermoFisher
Scientific) and 10 nM R1881 (LCG Group). PC-3M-
Pro4luc2 cells originate from serial passage of PC-3M cells
in the prostate of athymic mice [48] and were maintained in
DMEM medium: DMEM containing 4.5 g/L D-Glucose and
L-Glutamine (Gibco® LifeTechnologies™) supplemented with
10% FetalClone® II (HyClone™, GE Healthcare), 1% Penicil-
lin/Streptomycin (100U/L/100 μg/ml) and 0.8mg/mlG418
Geneticin® (Gibco®, LifeTechnologies™) for the selection of
luciferase positive clonal cell pools. The androgen-
independent DU145 cell line was first isolated from a brain
metastasis of a PCa patient [49] and was maintained in
DMEM (4.5 g/L D-Glucose) medium supplemented with
10% FBS and 1% Penicillin/Streptomycin (100U/L/100 μg/
ml). VCaP cells [50] were derived from a bone metastasis of
hormone refractory PCa and were maintained in RPMI
1640 medium with 2 g/L NaHCO3 and L-glutamine (Bio-
chrom) supplemented with 10% FBS and 1% Penicillin/
Streptomycin (100U/L/100 μg/ml). LNCaP cells were ori-
ginally derived from a lymph node metastasis [50] and
grown in T-medium: DMEM containing 1mg/L glucose
(Sigma Aldrich) supplemented with 20% F12K (Gibco®, Life-
Technologies™), 10% FBS, 1% Insulin-transferrin-selenium,
13.6 pg/ml T3, 0.25μg/ml Biotin, 25 μg/ml Adenine and 1%
Penicillin/Streptomycin (100U/L/100 μg/ml). An androgen-
independent cell line, C4–2 cells, was derived from LNCaP
cells by passaging in castrated mice [50]. C4–2 cells were
cultured in T-medium. All cell lines were maintained at
37 °C in an atmosphere containing 5% CO2 and were pas-
saged when they reached a confluency of 70–90%. For the
rescue experiment, cells were seeded and the total amount
of cells was passaged in bigger cell culture flasks when they
reached 80–90% confluency. The human cell lines employed
for functional characterisation in this study have been
authenticated using highly-polymorphic short tandem
repeat loci (STRs).
Cell cycle analysis
PC-3M-Pro4luc2 cells (20′000 cells/ml, 34′000 cells/ml
and 40′000 cells/ml) and C4–2 cells (20′000 cells/ml,
34′000 cells/ml and 44′000 cells/ml) were seeded in 5
ml complete medium. The next day, a mild cell cycle ar-
rest was induced by starvation for 48 h in the respective
standard medium containing 0.3% FC II or 0.3% FBS, re-
spectively. Starvation medium was replaced by complete
medium containing 10% FC II or 10% FBS, respectively,
and cell cycle progression was analysed at 0 h, 16 h and
48 h after cell cycle release. 250′000 cells were stained
by Propidium iodide (PI) staining in Nicoletti buffer
(0.1% Na3C6H5O7, 50 μg/ml PI and 0.1% Triton-X in
water) at 4 °C for 30 min and DNA content measured by
flow cytometry (BD™ LSR II). The percentage of cells in
G1, S and G2/M phase was analysed in FlowJo™ 10
(FlowJo LLC) by applying the Dean-Jett-Fox model.
Transfection
For transfection, 90′000 PC-3M-Pro4luc2 cells/ml and
150′000 C4–2 cells/ml were transfected with Lipofecta-
mine® 2000 Reagent (Invitrogen) in 2 ml Opti-MEM®
(Gibco®, LifeTechnologies™) according to the manufac-
turer’s protocol as described before [51]. Cells were trans-
fected with 10 nM hsa-miR-221-5p pre-miR™ miRNA
Precursor (miR-221-5p; assay ID: PM12613, Ambion), 10
nM Pre-miR™ Negative Control #1 (scrambled; assay ID:
AM17110, Ambion), 10 nM Anti-miR™ miRNA Inhibitor
hsa-miR-221-5p (anti-miR-221-5p; assay ID: AM12613,
Ambion) or 10 nM Anti-miR™ miRNA Inhibitor Negative
Control #1 (anti-scrambled; assay ID: AM17010, Ambion)
.
MTS assay
Transfected PC-3M-Pro4luc2 cells and C4–2 cells were
seeded at a density of 10′000 cells/ml or 20′000 cells/
ml, respectively, in 150 μl complete medium. 20 μl 3-(4,5
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS; CellTiter 96® AQue-
ous One Solution Cell Proliferation Assay, Promega)
were added to each well at indicated time points (0 h,
24 h, 48 h, and 72 h after seeding) and absorbance mea-
sured at 490 nm wavelength after 2 h incubation at
37 °C.
Clonogenicity assay
PC-3M-pro4luc2 cells were seeded at a density of 50
cells/ml and C4–2 cells at 400 cells/ml in 2 ml complete
DMEM or T-medium, respectively, and incubated at
37 °C for 14 days. The medium was re-freshed twice a
week and after 2 weeks the cells were fixed in 4% para-
formaldehyde (PFA) and stained with crystal violet
(Merck) 1:20 diluted in distilled water. Pictures of plates
were taken by ChemiDoc (BioRad) and colonies counted
by ImageJ 1.51j8 [52].
Migration assay
PC-3M-Pro4luc2 cells and C4–2 cells were starved
overnight in their respective standard medium contain-
ing 0.3% FC II or 0.3% FBS, respectively. The next day,
60′000 PC-3M-Pro4luc2 cells or 100′000 C4–2 cells
were seeded in 500ul starvation medium in Boyden
chambers with 8 μm pore size (Corning). Complete
medium containing 10% FC II or 10% FBS, respectively,
was added to the bottom of the well. PC-3M-Pro4luc2
cells and C4–2 cells were allowed to migrate for 22 h
and 27 h, respectively, and then fixed in 4% PFA and
stained with crystal violet as described by Zoni et al.
[51]. Five images per chamber were taken by bright field
microscope (Olympus) and migrated cells were counted.
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Zebrafish model
Tg(mpo:GFP)i114 zebrafish line [53, 54] was maintained
according to standard protocols (www.ZFIN.org). PC-3
M-Pro4 cells fluorescently labelled with mCherry (PC-
3M-Pro4_mCherry cells) were transfected with 10 nM
miR-221-5p or 10 nM scrambled 48 h before inoculation.
Zebrafish embryos were dechorionized at 2 days post fer-
tilisation (dpf), anaesthetized with 0.003% tricaine
(Sigma) and placed on 10 cm petri dish coated with 3%
agarose. A single cell suspension of transfected PC-
3M-Pro4_mCherry cells in PBS was kept at room
temperature and was loaded into borosilicate glass capil-
lary needles (1 mm O.D. × 0.78 mm I.D.; Harvard Appar-
atus). About 400 cells were injected above the ventral
end of the Duct of Cuvier, where the Duct of Cuvier
opens into the heart, using a Pneumatic Picopump and a
manipulator (WPI). Data are representative of at least
≥20 embryos per group. Survival rate of control group
lower than 80% was used as discard cut-off. After im-
plantation, zebrafish embryos were maintained at 33 °C
[55]. Images were taken at 1 day post injection (dpi) and
4dpi and red pixels were quantified by imageJ.
Orthotopic mouse model
Male, immunocompromised Balb/cByJ nude mice were
housed at the Central Animal Facility of the Medical
Faculty of the University of Bern in a specific pathogen-
free environment at a 12 h light/dark cycle. Mice had
free access to autoclaved chow and water and were
housed at a maximum of 5 animals/cage. Mice were
maintained and checked daily according to animal li-
cense. Animal experiments were approved by the Can-
ton of Bern, Switzerland (Permit Number: BE55/16), and
carried out in accordance with the Swiss Guidelines for
the Care and Use of Laboratory Animals and the AR-
RIVE guidelines. Mice were handled exclusively during
day time at the Central Animal Facility of the Medical
Faculty of the University of Bern. At the beginning of
the experiment, mice were 8-weeks old and weighed 22
g ± 2 g. To conduct this study, a total of 10 mice was
used to assess orthotopic growth of miR-221-5p overex-
pressing PC-3M-Pro4luc2 cells. PC-3M-Pro4luc2 cells
were transfected with 10 nM miR-221-5p and 10 nM
scrambled 48 h prior to inoculation. 8-weeks old male
Balb/cByJ nude mice (Charles River France) were allo-
cated to control group (scrambled: n = 5 mice) and ex-
perimental group (miR-221-5p = 5 mice). The mean
body weight was comparable in both groups at begin-
ning of the experiment. Mice were anaesthetized with
Domitor® (0.5 mg/kg)/Dormicum® (5 mg/kg)/Fentanyl
(0.05mg/kg) triple narcosis mix subcutaneous (s.c.) injec-
tion, which is well tolerated by the mouse strain, and the
eyes were protected by Vitamin A cream during surgery.
Approximately 50′000 single cells were reconstituted in
10 μl PBS and injected into the right lobe of the anterior
prostate. Surgeries were started in the morning with im-
plantation of miR-221-5p transfected PC-3M-Pro4luc2
cells. Mice of the second cage (n = 5) were injected with
scrambled transfected PC-3M-Pro4luc2 cells. Immedi-
ately after surgery, the mice were s. c. injected with anal-
gesic mix of Alzane® (1.1mg/kg)/Anexate® (0.45mg/kg)/
Temgesic® (0.075mg/kg) and received analgesia (Temge-
sic® 0.1 mg/kg) by s. c. injection twice a day for 3 days after
surgery. Tumor growth was screened weekly by assessing
bioluminescence with s. c. injection of 30 μl/mouse 250
mM D-Luciferin sodium salt (Synchem) and measuring by
NightOWL II LB983 in vivo imaging system (Berthold
Technologies). For BLI measurements, mice were anaes-
thetized by s. c. injection of Domitor® (0.5mg/kg)/Dormi-
cum® (5mg/kg)/Fentanyl (0.05mg/kg) triple narcosis mix
and received an antidote mix of Alzane® (1.02mg/kg)/
Anexate® (0.42 mg/kg)/Naloxon (0.6mg/kg) after meas-
urement. Animals without signal along the course of the
experiment were excluded from the analysis. At 28dpi the
bioluminescence signal reached more than 106cps and tu-
mors were dissected. Tumor volume was calculated as π/6
x length x width2 [56] and normalised to the body weight
(Additional file 1: Table S1). Tumor architecture and mo-
lecular markers were histologically characterised (see next
paragraph). After tumor dissection, the experiment was
terminated and all mice were euthanized by CO2
according to the recommendations of the Federal
Veterinary Office.
Histology and immunofluorescence stainings
Dissected tumors were formalin-fixed, paraffin-embedded
(FFPE) and cut in 4 μm sections for staining by haema-
toxylin and eosin (H&E). Images were taken by Pan-
noramic 250 Flash II Scanner (3D Histech Ltd). For
immunofluorescence, antigens of FFPE sections were
retrieved in boiling citrate buffer and sections blocked
in 1%BSA (Fluka)/PBS-Tween (Merck) for 30 min.
The sections were stained for monoclonal anti-human
proliferating cell nuclear antigen (PCNA; Cat.#: P8825,
Sigma Aldrich) 1:500, polyclonal anti-human cleaved
caspase-3 (cl. casp-3; Cat.#: 9661, Cell Signaling) 1:500,
polyclonal anti-human pan-cytokeratin (panCK; Cat.#:
A0575, DAKO) 1:250 and monoclonal anti-mouse α-
smooth muscle actin (α-SMA; Cat.#: A2547, Sigma
Aldrich) 1:400 in 1%BSA/PBS-Tween at 4 °C over-
night. Subsequently, sections were incubated with sec-
ondary antibodies AlexaFluor 488 donkey anti-mouse
(Cat.#: A-21202, LifeTechnologies™) 1:250 and AlexaFluor
555 donkey anti-rabbit (Cat.#: A-31572, LifeTechnologies™)
1:250 in PBS at room temperature for 1½ h. Images were
taken by LCI Leica DMI4000 B microscope (Leica
Microsystems).
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For phalloidin staining, PC-3M-pro4luc2 cells trans-
fected with 10 nM miR-221-5p or 10 nM scrambled were
stained with Acti-stain 488 Phalloidin (Cat.#: 176753,
abcam) according to manufacturer’s protocol. Briefly, 8′
000 cells/well were seeded on 8 chamber polystyrene
vessel tissue culture treated glass slides (Falcon) 24 h
post transfection and let attach for 48 h. Cells were fixed
in 4% PFA, permeabilised in 0.1% Triton-X in PBS and
stained with Acti-stain 488 Phalloidin for 40 min at
room temperature. Images were taken by LCI Leica
DMI4000 B microscope and analysed by imageJ for
mean phalloidin intensity normalised to the number
of nuclei.
RNA isolation and RT-qPCR
Total RNA was isolated from wild-type cell lines
(Ep156T, LNCaP, C4–2, VCaP, PC-3M-Pro4luc2 and
DU145 cells) or transfected PC-3M-pro4luc2 cells and
C4–2 cells 72 h post transfection by TriPure Isolation
Reagent (Roche) according to manufacturer’s protocol
with an additional wash with 90% ethanol after RNA
precipitation in isopropanol. For mRNA detection,
cDNA was synthesised from 500 ng total RNA by M-
MLV reverse transcriptase (Promega) and qPCR was
performed by FastStart Universal SYBR Green Master
Mix (Roche #04913850001) for EMT markers and
housekeeping genes HPRT and β-actin (see Additional
file 1: Table S2 for primer sequences). miRNA expres-
sion was analysed by cDNA synthesis from 2 ng total
RNA by TaqMan™ Advanced miRNA cDNA Synthesis
Kit (applied biosystems) and qPCR for hsa-miR-221-5p
TaqMan™ Advanced miRNA Assays (assay ID: 478778_
mir, applied biosystems) and housekeeping miRNAs hsa-
miR-103a-3p TaqMan® Advanced miRNA Assays (assay
ID: 478253_mir, applied biosystems) and hsa-miR-186-5p
TaqMan® Advanced miRNA Assays (assay ID: 477940_
mir, applied biosystems). Expression was normalised to
housekeeping genes or miRNAs, respectively, and results
are shown as relative expression calculated by 2-ΔCt or as
LOG difference calculated by LOG(2-ΔΔCt) method. Ct
values > 35 were excluded from the analysis.
Protein isolation and Western blot
Proteins were isolated 72 h post transfection with RIPA
buffer (150 mM NaCl, 1% Triton-X, 1% sodium deoxy-
cholate, 1% sodium dodecyl sulphate (SDS) in 25mM
Tris, pH 7.6) containing proteinase inhibitor (Roche) and
phosphatase inhibitor (Roche). Protein was quantified by
Pierce™ BCA protein assay kit (Thermo Scientific) accord-
ing to manufacturer’s protocol for microplate procedure.
20 μg of protein were denatured in Lämmli buffer (BioRad)
containing β-mercaptoethanol (Sigma Aldrich) by boiling
at 95 °C for 10min. Proteins were separated on a 12% SDS
PAGE gel and transferred to a PVDF transfer membrane
(Thermo Scientific). After blocking in 5% skimmed milk
(Carl Roth GmbH + Co KG) in TBS-Tween the mem-
branes were incubated with polyclonal goat anti-E-CAD
(Cat.#: AF648, R&D Systems) 1:1000 or monoclonal mouse
anti-VIM (Cat.#: ab8979, abcam) 1:1000 in 5% BSA in
TBS-Tween at 4 °C overnight. The next day, membranes
were incubated with mouse HRP-conjugated anti-β-actin
(Cat.#: A3854, Sigma Aldrich) 1:20′000 in 5% skimmed
milk and secondary antibodies HRP donkey anti-goat IgG
(Cat.#: ab97110, abcam) 1:10′000 and ECL™ peroxidase la-
belled anti-mouse (Cat.#: NA931VS, GE Healthcare) 1:10′
000 in TBS-Tween at room temperature for 1 h. Wester-
nBright™ ECL-HRP substrate (Witec) was added to the
membranes and images taken by Fusion-FX7–820 (Witec).
Protein bands were quantified by imageJ as described by
Luke Miller.org (https://lukemiller.org/index.php/2010/11/
analyzing-gels-and-western-blots-with-image-j/).
Statistics
The data was analysed by t-test, one-way ANOVA or
two-way ANOVA as indicated in the figure legends with
a confidence interval α ≤ 0.05. Data are shown as mean ±
SD. P values smaller than 0.05 were considered as statis-
tically significant (* p < 0.05, ** p < 0.01, *** p < 0.001, ****
p < 0.0001). For BLI data of mouse experiment, normal-
ity plot of residuals was checked to make sure it ap-
proximately follows a straight line. All statistical tests
were performed in GraphPad Prism 7.01 (GraphPad
Software) or R (The R Foundation).
Results
miR-221-5p is downregulated in PCa and PCa progression
To evaluate the relevance of miR-221 (5p and 3p) ex-
pression in PCa tissues, we analysed miR-221 expression
in the Taylor dataset (GSE21036) [45] providing miRNA
profiling data of tumor samples and normal adjacent tis-
sue after radical prostatectomy. We observed significant
downregulation of miR-221-5p (Fig. 1a; p < 0.001) and
miR-221-3p (Additional file 2: Figure S1A; p < 0.001) in
PCa samples compared to normal adjacent tissue. Fur-
ther downregulation of miR-221-5p (Fig. 1b; p < 0.001)
and miR-221-3p (Additional file 2: Figure S1B; p < 0.001)
was detected in the progression to metastasis compared
to primary tumor tissue. We furthermore analysed the
correlation between miR-221 expression, Gleason score
(GS) and tumor staging at surgery (RP) and diagnosis.
Significant miR-221-5p and miR-221-3p downregulation
was associated with increasing GS at surgery (Fig. 1c;
p < 0.01 for miR-221-5p; Additional file 2: Figure S1C;
p < 0.01 for miR-221-3p). In addition, miR-221-5p and
miR-221-3p were downregulated with increasing
pathological staging (Fig. 1d; p < 0.01 for miR-221-5p;
Additional file 2: Figure S1D; p < 0.01 for miR-221-3p).
However, we did not find a correlation between miR-221-
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5p or miR-221-3p expression and tumor staging at diag-
nosis (Additional file 2: Figure S1E & S1F). This study in-
vestigates specifically the functional role of miR-221-5p,
given its less understood role in PCa compared to miR-
221-3p.
miR-221-5p overexpression reduces cell growth and
colony formation in PCa cell lines
Endogenous miR-221-5p expression levels were studied
by Advanced miR TaqMan RT-qPCR in the normal
prostatic epithelial cell line Ep156T and different PCa
cell lines. We selected androgen receptor positive (AR+)
LNCaP cells, C4–2 cells and VCaP cells and androgen
receptor negative (AR−) PC-3M-Pro4luc2 and DU145
cell lines. The highest miR-221-5p expression was observed
in normal prostatic epithelial Ep156T cells compared to
PCa cell lines, regardless of AR status (Fig. 2a left panel;
p < 0.0001). Interestingly, AR− PCa cells expressed signifi-
cantly higher miR-221-5p levels than AR+ PCa cell lines
(Fig. 2a left panel; p < 0.001). Notably, miR-221-5p was dif-
ferentially expressed among AR+ cell lines (Fig. 2a right
panel). Androgen-sensitive LNCaP cells expressed higher
miR-221-5p levels than the LNCaP-derived, androgen-
independent C4–2 cell line (p < 0.001). Most pronounced
downregulation of miR-221-5p was observed in VCaP cells,
a cell line derived from human bone metastatic tissue
(p < 0.0001 compared to LNCaP cells, p < 0.05 compared to
C4–2 cells). The highest miR-221-5p expression was ob-
served in PC-3M-Pro4luc2 cells, which was significantly
higher than in DU145 cells (Fig. 2a right panel; p < 0.0001).
The AR− PC-3M-Pro4luc2 cells displaying high levels
of miR-221-5p and AR+ C4–2 cells expressing low
A B
C D
Fig. 1 miR-221-5p is downregulated during PCa progression in patient samples. a Analysis of GSE21036 dataset [45] for miR-221-5p expression in
PCa tissue compared to adjacent normal tissue. Fold change (FC = 0.83) to normal was calculated and data analysed by t-test. b Expression of
miR-221-5p in 14 metastatic PCa samples was compared to miR-221-5p expression in 99 primary PCa tissue in GSE21036 dataset. Fold
change (FC = 0.66) was calculated and data analysed by t-test. c Data of GSE21036 was grouped according to the indicated Gleason score (GS)
and miR-221-5p expression analysed. Adjusted p-value was calculated by one-way ANOVA. d miR-221-5p expression was analysed in samples grouped
for pathological stage (T). Data of GSE21036 was analysed by one-way ANOVA
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Fig. 2 miR-221-5p exerts tumor suppressive function on PCa cell lines in vitro. a Left: Relative miR-221-5p expression (2-ΔCt) in normal prostatic
epithelial Ep156T cells and AR+ and AR− PCa cell lines. Analysis by one-way ANOVA with Tukey’s multiple comparisons test. Right: Technical
replicates of at least two independent experiments for each cell line. miR-221-5p expression of AR+ cells was analysed by one-way ANOVA
with Tukey’s multiple comparisons test. AR− cell lines were compared by unpaired, two-tailed t-test. * p < 0.05, *** p < 0.001, **** p < 0.0001. Figure
symbols: cross: Ep156T; circle: LNCaP; square: C4–2; triangle: VCaP; filled circle: PC-3M-Pro4luc2; filled square: DU145 cells. b miR-221-5p expression
levels in PC-3M-Pro4luc2 cells upon overexpression or knock-down of miR-221-5p. LOG difference to control was calculated as LOG(2-ΔΔCt) and
analysed by unpaired, two-tailed t-test. Three technical replicates of representative experiments are shown. **** p < 0.0001 vs. scrambled, ## p < 0.01
vs. anti-scrambled. c Effect of miR-221-5p on proliferation. Images were taken 72 h post transfection with miR-221-5p and scrambled. MTS assay at 0 h,
24 h, 48 h, 72 h. Fold change compared to time point T’0 h was calculated for each time point. Data of n = 4 independent experiments are shown and
were analysed by two-way ANOVA repeated measures by both factors with Sidak’s multiple comparison test. * p < 0.05, ** p < 0.01. d Effect of anti-
miR-221-5p on proliferation. Images were taken at 72 h post transfection. MTS assay at 0 h, 24 h, 48 h, 72 h. Fold change compared to time point T’0 h
was calculated for each time point. Data represent n = 5 technical replicates and were analysed by two-way ANOVA repeated measures with Sidak’s
multiple comparison test. e Clonogenicity assay in miR-221-5p overexpressing PC-3M-Pro4luc2 cells. Dots indicate technical replicates of n= 4 independent
experiments. Fold change was calculated vs. scrambled control and analysed by unpaired, two-tailed t-test. *** p< 0.001. f Clonogenicity assay in miR-221-5p
knocked-down PC-3M-Pro4luc2 cells. N= 4 technical replicates are shown as fold change to control and analysed by unpaired, two-tailed t-test
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endogenous miR-221-5p levels were chosen to further
characterise miR-221-5p function in vitro. Despite
higher miR-221-5p expression, PC-3M-Pro4luc2 cells
proliferated faster than C4–2 cells. Cell cycle analysis by
PI staining showed a significantly higher fraction of PC-
3M-Pro4luc2 cells proceeding from G1 to S-phase at
16 h after release from cell cycle arrest resulting in an in-
creased fraction of PC-3M-Pro4luc2 cells in G2/M phase
compared to C4–2 cells at 48 h (Additional file 3: Figure
S2A; p < 0.01 for G1 and S-phase at 16 h; p < 0.05 for
G2/M at 48 h). The effect of miR-221-5p on PC-3M-
Pro4luc2 and C4–2 cells was further studied by overex-
pression and knock-down experiments. PC-3M-Pro4luc2
cells were transfected with 10 nM miR-221-5p or 10 nM
anti-miR-221-5p in order to overexpress or knock-down
miR-221-5p (Fig. 2b; p < 0.0001 for overexpression; p <
0.01 for knock-down; data normalized to respective
scrambled controls). Specificity of the anti-miR-221-5p
was confirmed by a co-transfection experiment. Anti-
miR-221-5p significantly antagonized the miR-221-5p
overexpression at concentrations as low as 10 nM
(Additional file 3: Figure S2B; p < 0.0001). At 120 nM con-
centration, anti-miR-221-5p partially rescued miR-221-5p
overexpression (Additional file 3: Figure S2B; p < 0.0001).
Similar miR-221-5p induction upon transfection of miR-
221-5p was achieved in the C4–2 cells (Additional file 3:
Figure S2C; p < 0.0001) and we assessed cell proliferation
of miR-221-5p transfected cells. miR-221-5p overexpres-
sion significantly decreased proliferation in PC-3M-
Pro4luc2 cells (Fig. 2c; p < 0.05 at 48 h, p < 0.01 at 72 h)
and C4–2 cells (Additional file 3: Figure S2D; p < 0.001 at
48 h, p < 0.0001 at 72 h) compared to control. miR-221-5p
knock-down in PC-3M-Pro4luc2 cells resulted in similar
proliferation rate compared to control (Fig. 2d).
The ability for unlimited self-renewal was studied
by clonogenicity assay. Overexpression of miR-221-5p
strongly reduced the number of colonies in PC-3M-
Pro4luc2 cells (Fig. 2e; p < 0.001) and C4–2 cells
(Additional file 3: Figure S2E; p < 0.0001) whereas this
was not altered by miR-221-5p knock-down (Fig. 2f ).
These data suggest a role of miR-221-5p in PCa cell
proliferation.
miR-221-5p affects cell plasticity and reduces cell migration
in vitro and extravasation in vivo
To understand whether miR-221-5p overexpression in-
duces a more epithelial phenotype, RNA was isolated
from miR-221-5p overexpressing PC-3M-Pro4luc2 cells
and C4–2 cells 72 h post transfection. The expression of
selected EMT markers including E-cadherin (E-CAD),
N-cadherin (N-CAD), vimentin (VIM), zinc finger E-
box-binding homeobox 2 (ZEB-2), SNAIL-1, SNAIL-2
and TWIST was analysed (Additional file 4: Figure S3A
& S3B). Subsequently, E-CAD/N-CAD and E-CAD/VIM
mRNA ratios were calculated. E-CAD mRNA expression
was significantly increased by miR-221-5p overexpression
in PC-3M-Pro4luc2 cells (Additional file 4: Figure S3A;
p < 0.05) leading to an increase in the E-CAD/N-CAD and
E-CAD/VIM mRNA ratio although this did not reach
significance (Fig. 3a). Notably, in C4–2 cells VIM was
significantly decreased by miR-221-5p overexpression
(Additional file 4: Figure S3B; p < 0.05). As a consequence,
E-CAD/VIM mRNA ratio was significantly increased in
miR-221-5p transfected C4–2 cells (Additional file 4:
Figure S3C; p < 0.05). We measured the effect of miR-221-
5p on E-CAD and VIM protein by western blot. E-CAD
expression remained unchanged while VIM showed a
trend for downregulation by miR-221-5p overexpression
compared to control in PC-3M-Pro4luc2 cells (Fig. 3b and
Additional file 4: Figure S3D). The E-CAD/VIM protein
ratio was significantly elevated in miR-221-5p transfected
PC-3M-Pro4luc2 cells compared to control (Fig. 3b; p <
0.01). In C4–2 cells, we observed a trend for E-CAD pro-
tein downregulation upon miR-221-5p overexpression
(Additional file 4: Figure S3E & S3F) resulting in de-
creased E-CAD/VIM ratio (Additional file 4: Figure
S3F; p < 0.05).
To evaluate whether the differential expression of
EMT markers in miR-221-5p transfected cells correlates
with functional changes, we studied the effect of miR-
221-5p on migration by transwell migration assay. The
migration of PC-3M-Pro4luc2 cells was significantly re-
duced by miR-221-5p overexpression (Fig. 3c; p <
0.0001) while miR-221-5p knock-down had no effect on
migration (Fig. 3d). Consistently, miR-221-5p overex-
pression resulted also in decreased migration in C4–2
cells (Additional file 4: Figure S3G; p < 0.0001).
Moreover, we investigated if miR-221-5p affected the
structure of the cytoskeleton by phalloidin staining on
miR-221-5p transfected PC-3M-Pro4luc2 cells. F-actin
polymerisation was increased, though not significant, by
miR-221-5p transfection in PC-3M-Pro4luc2 cells
(Fig. 3e). We did not observe a difference in the
morphology of the cells.
We studied the effect of miR-221-5p on extravasation
in vivo in our established zebrafish model [51, 57]. Fluo-
rescently labelled, transiently miR-221-5p overexpressing
PC-3M-Pro4 cells expressing the fluorescent protein
mCherry (PC-3M-Pro4_mCherry) were injected into the
Duct of Cuvier of zebrafish embryos 2 days post
fertilization (dpf ). PC-3M-Pro4_mCherry cells overex-
pressing miR-221-5p formed fewer and smaller meta-
static foci in the caudal hematopoietic tissue (CHT) and
the tumor burden was reduced by miR-221-5p overex-
pression 4 days post injection (dpi) (Fig. 3f; p < 0.01).
Taken together, these data suggest that miR-221-5p
overexpression modulates EMT markers and migration
in vitro. In line with our in vitro data, miR-221-5p
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Fig. 3 Overexpression of miR-221-5p affects plasticity of PCa cells and reduces extravasation in vivo. a E-CAD/N-CAD and E-CAD/VIM ratios were
calculated from the relative mRNA expression and data of n = 3 independent experiments are shown as fold change to control. Data were analysed
by paired, two-tailed t-test. b Expression of E-CAD and VIM protein in PC-3M-Pro4luc2 cells 72 h post transfection with miR-221-5p and scrambled.
Bands were quantified and E-CAD/VIM ratio was calculated (normalised to β-actin). The data of n = 2 independent experiments are shown as fold
change to scrambled and were analysed by paired, two-tailed t-test. ** p < 0.01. c Migration of miR-221-5p overexpressing PC-3M-Pro4luc2 cells. Dots
represent technical replicates of n = 3 independent experiments. Data are shown as fold change to scrambled and were analysed by unpaired,
two-tailed t-test. **** p < 0.0001. d Migration of PC-3M-Pro4luc2 cells with miR-221-5p knock-down. N = 3 technical replicates are shown.
Data were normalised to control and analysed by unpaired, two-tailed t-test. e Phalloidin staining in PC-3M-Pro4luc2 cells overexpressing
miR-221-5p or scrambled control. F-actin signal was normalised to number of nuclei. Data was analysed by unpaired, two-tailed t-test.
F-actin = green; DAPI = blue. f Extravasation of miR-221-5p and scrambled transfected PC-3M-pro4_mCherry cells at the caudal hematopoietic tissue
(CHT) of zebrafish embryos 4 days post injection (dpi). Tumor burden was quantified 1dpi and 4dpi. Green = vessels; red = PC-3M-pro4_mCherry cells.
Data was analysed by unpaired, two-tailed t-test. ** p < 0.01
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overexpression decreases extravasation at CHT in zebrafish
leading to reduced metastatic growth.
miR-221-5p overexpression reduces prostate tumor
growth in vivo
To investigate the effect of miR-221-5p on tumor
growth, we studied miR-221-5p overexpressing PC-3M-
Pro4luc2 cells in vivo in an orthotopic mouse model.
PC-3M-Pro4luc2 cells were transfected with miR-221-5p
or scrambled and injected into the anterior prostate of
Balb/cByJ nude male mice. Overexpression of miR-221-
5p was confirmed by RT-qPCR (Additional file 5: Figure
S4A; p < 0.0001) and clonogenicity was tested on the
same batch of cells used for anterior prostatic implant-
ation (Additional file 5: Figure S4B). Tumor growth was
screened weekly by bioluminescence imaging (BLI)
(Additional file 5: Figure S4C) and body weight was reg-
istered along the course of the experiment (Fig. 4a).
miR-221-5p overexpression significantly reduced tumor
growth compared to control in vivo (Fig. 4b; p < 0.01, 28
days after cells implantation). Moreover, miR-221-5p
overexpression resulted in a significantly lower tumor
volume (normalised to body weight) compared to con-
trol group (Fig. 4c; p < 0.05; Additional file 5: Figure S4D
and Additional file 1: Table S1). Histological evaluation
by hematoxilin and eosin (H&E) staining revealed no
difference between miR-221-5p overexpressing and con-
trol tumors (Fig. 4d and Additional file 6: Figure S5).
The sections were stained for proliferation and apoptosis
markers (proliferating cell nuclear antigen (PCNA) and
cleaved caspase-3 (cl. casp-3)). Despite the differences in
tumor growth and volume, no difference in the level of
proliferating and apoptotic cells between miR-221-5p
and control was detected by PCNA and cl. casp-3 im-
munofluorescence staining (Fig. 4d and Additional file 6:
Figure S5). In order to evaluate whether miR-221-5p
levels affected the tumor composition regarding tumor
cell burden and stroma contribution, the tumor sections
were stained for tumor cell specific marker panCK and
stromal marker α-smooth muscle actin (α-SMA). We ob-
served a similar pattern between miR-221-5p and scram-
bled control (Fig. 4d and Additional file 6: Figure S5).
Taken together, these data demonstrated that miR-
221-5p overexpression reduced tumor growth in vivo
without affecting apoptosis or the features of the tumor
associated stroma.
Loss of miR-221-5p overexpression rescues proliferation,
colony formation and migration capacity of aggressive
PCa cells in vitro
To investigate the kinetic of miR-221-5p expression fol-
lowing transfection, we evaluated miR-221-5p expression
levels at different time points, early after transfection
(72 h post transfection) and at 2 weeks. miR-221-5p
expression levels were correlated to functional changes
by assessing proliferation, clonogenicity and migration at
an early time point and a late time point (Fig. 5a). RNA
was isolated from transfected cells 72 h and 2 weeks post
transfection (Fig. 5a). miR-221-5p was significantly over-
expressed 72 h post transfection compared to scrambled
control (Fig. 5b; p < 0.0001 at 72 h). After 2 weeks in cul-
ture, the miR-221-5p levels had significantly decreased
(p < 0.0001) though were still significantly overexpressed
compared to control (Fig. 5b; p < 0.001 at week 2). Over-
expression of miR-221-5p led to significantly reduced
cell number than control at day 3 (p < 0.0001), day 6
(p < 0.01) and day 9 (p < 0.001) post transfection suggest-
ing reduced cell growth (Fig. 5c). At day 12 post trans-
fection, the cell number in miR-221-5p transfected cells
equalled to control (Fig. 5c). At the early time point,
proliferation (Fig. 5d; p < 0.001 at week 1), clonogenicity
(Fig. 5e) and migration (Fig. 5f; p < 0.0001 at week 1) of
miR-221-5p transfected PC-3M-Pro4luc2 cells were re-
duced compared to control though clonogenicity did not
reach significance. At the late time point, the effect of
miR-221-5p overexpression on proliferation (Fig. 5d; p <
0.01), clonogenicity (Fig. 5e) and migration (Fig. 5f; p <
0.0001) was lost compared to early time point. Notably,
the migration capacity of miR-221-5p transfected cells
was significantly higher compared to control at the late
time point (Fig. 5f; p < 0.01 at week 2). We also evalu-
ated the expression of selected EMT markers at the early
and late time point after transfection. At 72 h post transfec-
tion, E-CAD mRNA expression was increased in miR-221-
5p overexpressing PC-3M-Pro4luc2 cells (Additional file 7:
Figure S6 left panel; p < 0.0001 at 72 h) resulting in in-
creased E-CAD/N-CAD ratio and E-CAD/VIM ratio com-
pared to control (Fig. 5g; p < 0.0001 at 72 h for both ratios).
2 weeks post transfection, the expression of EMT markers
displayed a different pattern compared to early time point
(Additional file 7: Figure S6 right panel) and the E-CAD/N-
CAD ratio and E-CAD/VIM ratio had significantly de-
creased to similar levels as the control (Fig. 5g; p < 0.0001
for both ratios).
These data demonstrate that the observed func-
tional and transcriptional changes correlate with miR-
221-5p levels.
Discussion
In this in vitro and in vivo preclinical study, we demon-
strated that miR-221-5p acts as tumor suppressor in
PCa. miR-221 is generally overexpressed in epithelial
cancers and plays an oncogenic role [21]. However, in
prostate cancer, oncogenic [25, 34, 35, 44, 58] and tumor
suppressive function for miR-221 have been described
[27, 28, 41, 42]. Here we reported downregulation of
miR-221-5p in PCa cell lines compared to non-
cancerous prostatic epithelial Ep156T cells implying an
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important role for miR-221-5p in the maintenance of a
normal epithelial phenotype. Proliferation was decreased
by miR-221-5p overexpression in PC-3M-Pro4luc2 cells
and C4–2 cells. Notably, we observed faster cell cycle
progression in PC-3M-Pro4luc2 cells than in C4–2 cells
despite higher baseline expression of miR-221-5p in PC-
3M-Pro4luc2 cells. The high proliferation rate of PC-
3M-Pro4luc2 cells can be attributed to their high expres-
sion of TGF-α and EGF-R as well as p53 mutation and
PTEN deficiency which might compensate for intrinsic-
ally higher miR-221-5p levels [59]. However, miR-221-5p
overexpression significantly reduced proliferation of PC-
3M-Pro4luc2 cells. Knock-down of miR-221-5p had no
functional effects on PC-3M-Pro4luc2 cells. Despite spe-
cific action of anti-miR-221-5p, we achieved a miR-221-
5p downregulation of 40%. Given the redundant action
of miRNAs and the endogenously low miR-221-5p ex-
pression levels in PCa cell lines compared to normal
prostatic epithelial cells, the in vitro miR-221-5p down-
regulation might be too weak to see a positive functional
effect. Previously published work demonstrated miR-
221-5p overexpression to reduce proliferation of PCa
cells by downregulation of cell cycle regulatory proteins
[27]. However, miR-221-5p overexpression has also been
reported to promote proliferation of PCa cell lines by ac-
tivating Ras/Raf/MEK/ERK pathway and consequently
A
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Fig. 4 Orthotopic tumor growth is reduced by miR-221-5p overexpression in vivo. a Body weight was measured weekly along the course of the
in vivo experiment (n = 4 for miR-221-5p and scrambled control). Data was analysed by two-way ANOVA repeated measures with Sidak’s multiple
comparison test. b BLI imaging of mice injected with miR-221-5p or scrambled negative control. One representative image of each group is
shown at 7 and 28 days. Tumor growth was quantified by overall counts per second (cps) from four animals per group (n = 4). The data was
analysed by two-way ANOVA repeated measures with Sidak’s multiple comparison test. ** p < 0.01. c Tumor volume of miR-221-5p and scrambled
overexpressing PC-3 M-Pro4luc2 cells was calculated as V = π/6 x length x width2 and normalised to the body weight. Data was analysed by unpaired,
two-tailed t-test. * p < 0.05. Scale bar = 5mm. d H&E of scrambled and miR-221-5p group (left panel). The expression of proliferation marker PCNA
(green; middle panel), apoptosis marker cleaved caspase-3 (cl. casp-3; red; right panel), tumor cell marker panCK (red; middle panel) and stroma marker
α-SMA (green; right panel) was analysed by immunofluorescence staining
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Fig. 5 miR-221-5p-induced functional changes correlate to miR-221-5p (over)expression levels. a Experimental design of the rescue experiment
after miR-221-5p overexpression. b miR-221-5p expression in PC-3M-Pro4luc2 cells 72 h and 2 weeks post transfection. miR-221-5p expression was
normalised to housekeeping miRNAs and LOG difference to control (LOG(2-ΔΔCt)) is shown. Data are representative of n = 3 technical replicates
and were analysed by one-way ANOVA with Tukey’s multiple comparison. *** p < 0.001, **** p < 0.0001. c Cell growth estimated by counting the
total number of cells at different time points post transfection (1, 3, 6, 9, 12 and 14 days). Data represent technical replicates and were analysed
by two-way ANOVA repeated measures with Sidak’s multiple comparison test. ** p < 0.01, *** p < 0.001, **** p < 0.0001. d MTS assay for proliferation
of miR-221-5p or scrambled transfected PC-3M-Pro4luc2 cells starting 24 h or 2 weeks post transfection. Data of n = 10 technical replicates were
normalised to T’0 h and fold change to scrambled at T’72 h was calculated. Data were analysed by one-way ANOVA with Tukey’s multiple
comparison test. ** p < 0.01, *** p < 0.001. e Clonogenicity assay in PC-3M-Pro4luc2 cells overexpressing miR-221-5p or scrambled control
at early and late time point. Data are representative of n = 4 technical replicates and fold change vs. scrambled represented. Data was
analysed by one-way ANOVA with Tukey’s multiple comparison test. f Migration assay in PC-3M-Pro4luc2 cells overexpressing miR-221-5p
or scrambled negative control at 1 and 2 weeks post transfection. The number of migrated cells was counted and the fold change to scrambled
calculated. Data of technical triplicates was analysed by one-way ANOVA with Tukey’s multiple comparison test. ** p< 0.01, **** p< 0.0001. g E-CAD/N-
CAD and E-CAD/VIM mRNA ratio of miR-221-5p and scrambled overexpressing PC-3M-Pro4luc2 cells. Data of n= 3 technical replicates are shown as fold
change to scrambled and were analysed by one-way ANOVA with Tukey’s multiple comparison test. **** p< 0.0001
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stable silencing of miR-221-5p reduced tumor growth of
PCa cell xenografts [44]. These studies imply that miR-
221-5p targets a multitude of pathways and acts as
tumor suppressor or oncogenic miRNA depending on
the cellular and experimental conditions. For a better
understanding of miR-221-5p function during PCa
growth, we studied miR-221-5p in a transient overex-
pression orthotopic in vivo model. miR-221-5p overex-
pression significantly reduced tumor growth and tumor
volume compared to control. Tumors did not display
differences in proliferation or apoptosis rates as deter-
mined by PCNA and cl. casp-3 staining, which is likely
due to the loss of overexpressed miR-221-5p in the
course of the in vivo experiment. Indeed, miR-221-5p di-
minished significantly over 2 weeks after overexpression
in vitro, which was associated with loss of effect on pro-
liferation. This supports the hypothesis that the observed
tumor suppressive effects are dependent on miR-221-5p
(over)expression levels and might also account for the
lack of detectable direct effects of miR-221-5p overex-
pression in the dissected tumors. While there is still a
significant difference in tumor growth in vivo after 28
days, the effect of miR-221-5p overexpression on cell
growth was lost after 12 days in vitro (Fig. 5c). This is
due to the fact that control cells reached confluency
earlier than miR-221-5p overexpressing cells and were
not proliferating anymore. In contrast, scrambled trans-
fected cells proliferated at a high rate at 2 weeks post in-
jection in vivo and did not experience any spatial
limitations for growth. Despite transient transfection,
miR-221-5p overexpression reduced tumor burden sig-
nificantly in vivo suggesting an initially large inhibitory
effect of miR-221-5p overexpression on PCa growth.
Our data imply that transient miR-221-5p overexpres-
sion reduces PCa cell proliferation in vitro and influ-
ences the growth kinetic of orthotropic tumors in vivo.
Analysis of publicly available microRNA dataset
(GSE21036) [45] led us to the finding that miR-221-5p
expression is progressively decreased in PCa tumor and
further decreases in metastasis. Low miR-221-5p expres-
sion correlated with lower histological differentiation as
assessed by Gleason score and with disease progression
as assessed by TNM staging, indicating that miR-221-5p
downregulation is a pre-requisite for local and advanced
disease in PCa patients. The significance of miR-221 as
tumor suppressor in PCa is supported by the notion,
that miR-221 is downregulated in clinical specimens of
TMPRMSS2:ERG fusion positive PCa, which comprise
over 50% of all diagnosed tumors [60]. Moreover, low
miR-221 levels in PCa tissue are associated with earlier
recurrence after radical prostatectomy [61].
The ability to undergo unlimited division and to form
clones is an essential feature of aggressive cancer cells.
miR-221-5p overexpression significantly reduced colony
formation suggesting that miR-221-5p might interfere
with self-renewal mechanisms. Interestingly, murine
miR-221-5p has been shown to directly target and
downregulate Oct4, Nanog, Sox2, Klf4 and PRMT7 in
mouse embryonic stem cells thereby functioning as
“anti-stemness” miRNA [62]. In human PCa cells, miR-
221-3p has been shown to target the stem cell factor
Bmi-1 [41]. Oct4, Nanog, Sox2 and Bmi-1 are upreg-
ulated in PCa tissue and tumor-initiating PCa cells
[63, 64]. However, additional studies are required to
elucidate the mechanistic effect of miR-221 and its
interaction with transcription factors implicated in
self-renewal and cell dedifferentiation, leading to highly
aggressive, metastatic disease.
Epithelial-to-mesenchymal transition (EMT) is an
established characteristic of highly aggressive cancer
cells. Differential expression of E-CAD, N-CAD or VIM
upon miR-221-5p overexpression has already been re-
ported in PCa cell lines [27, 44]. We showed that miR-
221-5p overexpression induced an increase of the E-
CAD/VIM ratio on mRNA and protein level in PC-3M-
Pro4luc2 cells leading to a more epithelial phenotype,
which can be mainly attributed to a decrease of VIM
protein expression. In contrast to the highly mesenchy-
mal PC-3M-Pro4luc2 cells, C4–2 cells express intrinsic-
ally lower VIM levels, which are not affected by miR-
221-5p overexpression leading to a decreased E-CAD/
VIM ratio in miR-221-5p overexpressing C4–2 cells.
Our data support the notion that the EMT expression
profile of PC-3M-Pro4luc2 cells and C4–2 cells are dif-
ferentially affected by miR-221-5p overexpression. Add-
itionally, miR-221-5p overexpression reduced migration
of both cell lines dramatically. PC-3M-Pro4luc2 cells
display elongated morphology and migrate in a “mesen-
chymal manner” [65]. In contrast, C4–2 cells show a less
mesenchymal phenotype and migrate in an “amoeboid
manner” [65, 66]. We have previously shown that differ-
ent molecular mechanisms support motility in PC-3M-
Pro4luc2 and C4–2B cells [51]. Interestingly, with the di-
minished miR-221-5p overexpression levels 2 weeks post
transfection the migration of PC-3M-Pro4luc2 cells was
significantly increased compared to control (Fig. 5f ). It
has previously been shown for miR-430 that miRNAs
can balance the expression of agonist/antagonist pairs
[67]. Similarly, the moderately increased miR-221-5p
levels at 2 weeks post transfection in combination with
cellular compensatory mechanisms [12, 68] might have
led to an imbalance between positive and negative regu-
lators of migration resulting in increased migration. The
ability to migrate is a pre-requisite for tumor cell
extravasation and metastasis formation. This highly dy-
namic process requires engagement of adhesion mole-
cules including selectins, cadherins, integrins, CD44 and
immunoglobulin superfamily receptors [69]. In line with
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the modulation of E-CAD and VIM expression and
reduced migration in vitro by miR-221-5p overexpres-
sion, extravasation of highly aggressive PC-3M-Pro4_
mCherry cells was reduced by miR-221-5p in vivo, in
a zebrafish model of tumor cell extravasation. miR-
221-5p transfected PC-3M-Pro4_mCherry cells formed
less and smaller metastatic foci at the caudal hematopoietic
tissue (CHT) of zebrafish embryos, suggesting a critical role
of miR-221-5p to prevent extravasation at distant sites.
These results matched our in vitro observations and simi-
larly as in the mouse experiment, miR-221-5p overexpres-
sion reduced tumor burden in zebrafish embryos.
Taken together, our findings and the loss of miR-221
during PCa progression [27, 33], might suggest a role for
miR-221 in counteracting tumor cell migration and me-
tastasis formation. Accordingly, we found lower miR-
221-5p levels in the more advanced, androgen-
independent C4–2 cells compared to the parental,
androgen-dependent LNCaP cell line [50]. VCaP cells
were derived from a vertebral metastasis and represent a
model of advanced, metastatic PCa. miR-221-5p levels
were nearly undetectable in VCaP cells. This finding
aligns with downregulation of miR-221-5p in metastatic
disease compared to primary tumor as we found by ana-
lysis of a publicly available patient dataset. Increased
methylation of the miR-221/− 222 locus and miR-221-5p
suppression has been associated with metastatic PCa
and might contribute to disease progression [27]. We
observed higher miR-221-5p expression in AR− cell lines
than in AR+ PCa cell lines, which is possibly due to the
absence of AR, a transcriptional repressor of the miR-
221/− 222 gene cluster [70]. ADT resistance and
progression to metastasis is often linked to restored AR
activity [71], which potentially leads to repression of
miR-221/− 222 in CRPC and could further promote PCa
progression in this critical phase. However, additional
experiments are necessary to elucidate the relation be-
tween miR-221-5p and AR status.
Conclusion
Dataset analysis revealed downregulation of miR-221
(3p and 5p) during PCa progression and suggests a
tumor suppressive role of miR-221 in PCa patients.
We report that miR-221-5p acts as tumor suppressor
miRNA in PCa cell line models and reduces tumor
burden in mouse and zebrafish in vivo models. miR-
221 was identified as key regulator of a network of
other miRNAs in PCa [31] and has the potential to
drastically modulate cell physiology. Therefore, a bet-
ter understanding of miR-221 function in the context
of PCa will potentially lead to the identification of
novel interactions between signalling pathways that
promote PCa progression.
Additional files
Additional file 1: Table S1. Body weight and tumor size of mouse in
vivo experiment. Table S2: Primer sequences. (DOCX 16 kb)
Additional file 2: Figure S1. miR-221 is downregulated during PCa
progression in patient samples. (a) microRNA dataset analysis in GSE21036
dataset. Expression of miR-221-3p in 113 PCa samples compared to 28
normal tissue samples. Fold change (FC = 0.85) was calculated and data was
analysed by t-test. (b) Analysis of miR-221-3p expression in metastatic PCa
samples compared to primary PCa tissue in GSE21036 dataset. Fold change
(FC = 0.74) was calculated and data analysed by t-test. (c) Data of GSE21036
was grouped according to the indicated Gleason score (GS) and miR-221-3p
expression analysed. Adjusted p-value was calculated by one-way ANOVA.
(d) miR-221-3p expression (GSE21036) was analysed in samples grouped for
pathological stage (T). Data was analysed by one-way ANOVA. (e) Analysis of
miR-221-5p expression in samples grouped for clinical stage (T) in GSE21036
dataset. Data was analysed by one-way ANOVA. (f) Analysis of miR-221-3p
expression in sample groups according to clinical stage (T). Data of
GSE21036 was analysed by one-way ANOVA. (PDF 280 kb)
Additional file 3: Figure S2. miR-221-5p exerts tumor suppressive func-
tion on PCa cell lines in vitro. (a) Cell cycle of wild-type PC-3 M-Pro4luc2
and C4–2 cells was analysed by PI staining at 0 h, 16 h and 48 h after re-
lease starvation. The frequency of cells in G1, S and G2/M phase was
quantified by Dean-Jett-Fox model. Results of n = 2 technical replicates
were analysed by unpaired, two-tailed t-test. * p < 0.05, ** p < 0.01. (b)
PC-3 M-Pro4luc2 cells were transfected with 10 nM miR-221-5p or 10 nM
scrambled. The next day, cells were transfected with increasing concen-
trations of anti-miR-221-5p (10 nM, 20 nM, 30 nM, 60 nM and 120 nM) or
10 nM anti-scrambled. miR-221-5p expression was assessed 48 h later
and LOG difference (LOG(2-ΔΔCt)) to scrambled/anti-scrambled co-
transfection control calculated. Data of n = 3 technical replicates are rep-
resented and were analysed by two-way ANOVA with Sidak’s multiple
comparison test. **** p < 0.0001 miR-221-5p/anti-miR-221-5p compared
to scrambled/anti-scrambled control, #### p < 0.0001 scrambled/anti-miR-
221-5p compared to scrambled/anti-scrambled control, p < 0.0001 miR-
221-5p/anti-miR-221-5p compared to scrambled/anti-miR-221-5p. (c) miR-
221-5p overexpression in C4–2 cells 72 h post transfection with miR-221-
5p or scrambled control. LOG difference to scrambled was calculated as
LOG(2-ΔΔCt). Data of one representative experiment are shown and were
analysed by unpaired, two-tailed t-test. **** p < 0.0001. (d) Proliferation of
miR-221-5p and scrambled overexpressing C4–2 cells. Images were taken
72 h post transfection. Proliferation was measured by MTS at four time
points (0 h, 24 h, 48 h and 72 h). Data of n = 3 independent experiments
are shown as fold change normalised to T’0 h and were analysed by
two-way ANOVA with repeated measures by both factors with Sidak’s
multiple comparison test. *** p < 0.001, **** p < 0.0001. (e) Clonogenicity
assay of C4–2 cells transfected with miR-221-5p or scrambled. All tech-
nical replicates of three independent experiments (n = 3) were pooled
and fold change to scrambled was calculated. Data were analysed by un-
paired, two-tailed t-test. **** p < 0.0001. (PDF 245 kb)
Additional file 4: Figure S3. miR-221-5p overexpression affects plasticity
of PCa cells and EMT marker expression. (a) EMT marker expression in PC-3
M-Pro4luc2 cell overexpressing miR-221-5p or negative scrambled control.
Data of three independent experiments (n = 3) are shown as LOG difference
to control (LOG(2-ΔΔCt)) and were analysed by paired, two-tailed t-test.
* p < 0.05, ** p < 0.01. (b) EMT marker expression in miR-221-5p or scrambled
overexpressing C4–2 cells. Results of three independent experiment (n = 3)
are shown as LOG difference to control (LOG(2-ΔΔCt)) and were analysed by
paired, two-tailed t-test. * p < 0.05; n.d. = not detectable. (c) E-CAD/VIM
mRNA ratio of miR-221-5p and scrambled overexpressing C4–2 cells was
calculated from relative expression (2-ΔCt) and is shown as fold change to
scrambled. Results of three independent experiments are shown (n = 3).
Data were analysed by paired, two-tailed t-test. * p < 0.05. (d) E-CAD and
VIM protein expression in PC-3 M-Pro4luc2 cells 72 h post transfection with
miR-221-5p or scrambled. Protein expression was normalised to β-actin and
fold change to scrambled was calculated for n= 2 independent experiments.
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Data were analysed by paired, two-tailed t-test. (e) E-CAD and VIM protein
expression in miR-221-5p or scrambled overexpressing C4–2 cells 72 h post
transfection. Protein expression was normalised to housekeeping β-actin and
fold change to scrambled negative control calculated. Data of n= 2 technical
replicates are shown and were analysed by unpaired, two-tailed t-test. (f)
Western blot for E-CAD and VIM in C4–2 cells overexpressing miR-221-5p or
scrambled. Bands were quantified and normalised to housekeeping protein β-
actin and E-CAD/VIM ratio was calculated. N= 2 technical replicates are shown
as fold change to scrambled and were analysed by unpaired, two-tailed t-test.
* p< 0.05. (g) Migration of miR-221-5p or scrambled overexpressing C4–2 cells.
All technical replicates of three independent experiments (n= 3) are shown as
fold change to scrambled. Data were analysed by unpaired, two-tailed t-test.
**** p< 0.0001. (PDF 215 kb)
Additional file 5: Figure S4. Orthotopic tumor growth is reduced by
miR-221-5p overexpression in vivo. (a) miR-221-5p expression in PC-3
M-Pro4luc2 cells 48 h post transfection, prior to intraprostatic injection in
mice. Data are shown as LOG difference (LOG(2-ΔΔCt)) to scrambled and
were analysed by unpaired, two-tailed t-test. **** p< 0.0001. (b) Clonogenicity
assay of miR-221-5p overexpressing PC-3M-Pro4luc2 cells. Same batch of cells
was used for in vivo inoculation. Data were analysed by unpaired, two-tailed
t-test. (c) BLI images of all mice are shown at 7 and 28 days post implantation.
Mice without detectable BLI signal (M4 and M10) at the end of the
experiment were omitted from further analysis. (d) Tumors dissected
from mice injected with miR-221-5p or scrambled transfected PC-3M-Pro4luc2
cells at the end of the experiment. Images and tumor volume of all mice are
shown. Scale bar = 5mm. (PDF 352 kb)
Additional file 6: Figure S5. Morphology of orthotopically grown PC-3
M-Pro4luc2 tumors is not affected by miR-221-5p overexpression. H&E
and immunofluorescence imaging of all dissected tumors. The expression
of proliferation marker PCNA (green), apoptosis marker cl. casp-3 (red),
tumor cell marker panCK (red) and stroma marker α-SMA (green) was
analysed by immunofluorescence staining. Representative images of each
mouse are shown. (PDF 988 kb)
Additional file 7: Figure S6. Differential EMT marker expression at early
and late time point post transfection. Expression of selected EMT markers
in PC-3M-Pro4luc2 cells at 72 h and 2weeks post transfection. LOG difference
was calculated as LOG(2-ΔΔCt) normalised to scrambled. Results of n = 3
technical triplicates are shown and data were analysed by unpaired,
two-tailed t-test. * p < 0.05, ** p < 0.01, **** p < 0.0001. (PDF 35 kb)
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